Given the newly uncovered role for mTOR in production of antiphospholipid antibodies outside [94] or within the context of SLE [95,96], KYN should be considered a metabolic trigger of thrombosis through the tissue factor-plasminogen activator inhibitor 1 axis (Figure 2) [93]. The gene discussed is MTOR; the disease is systemic lupus erythematosus.